Myriad Genetics

MYGNNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$384.512 M

$4.02 +0.25%

Close of 22 Sept 2026

Revenue

$824.5M

#1638 by revenue

Earnings

-$366.0M

Loss-making

Shares outstanding

95,649,645

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#9QuidelOrthoQDEL$750.2M
#10Alpha TeknovaTKNO$470.8M
#11Myriad GeneticsMYGN$384.5M
#12Insight Molecular DiagnosticsIMDX$135.5M
#13ImmucellICCC$90.7M

What if Myriad Genetics were worth as much as…

Open the what-if tool →

Gold $30.2T

$316,090.77

Per share 78,630× higher

Bitcoin $1.74T

$18,208.69

Per share 4,530× higher

Nvidia $5.52T

$57,666.36

Per share 14,345× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Myriad Genetics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.